Beta Drugs Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32

Beta Drugs Limited has submitted a statement of deviation or variation to the stock exchange as required under Regulation 32 of the SEBI Listing Regulations. This filing typically relates to the company's use of funds raised through a recent IPO, FPO, or preferential allotment. The specific nature of the deviation or variation, along with revised use of proceeds, is not detailed in the headline. Reg 32 filings are mandatory disclosures whenever the actual deployment of raised funds differs from the objects stated in the original offer document.